Search

The article discusses a clinical trial, NCT06778005, conducted at Sultan Abdulhamid Han Training and Research Hospital in Istanbul, Turkey, focusing on evaluating ultrasonographic measurements of lower extremity nerves in patients with diabetic polyneuropathy. The study aims to investigate the relationship between these measurements and gait, balance performance, and quality of life in diabetic patients. Various diagnostic tests and assessments will be conducted, including ultrasonography, the Biodex balance system, pain scales, quality of life assessments, and physical activity questionnaires. The study involves healthy volunteers and patients with diabetic polyneuropathy, with a total of 86 participants, and is scheduled to be completed by July 1, 2025. [Extracted from the article]

A patent has been issued for a mechanistic bacterial effector that aims to prevent apoptosis of human beta cells in individuals with Type 1 diabetes. The patent, assigned to the University of Florida Research Foundation, focuses on the use of microvesicles isolated from Lactobacillus johnsonii to inhibit apoptotic and pre-apoptotic human pancreatic beta cells. This composition may be administered to diabetic, pre-diabetic, or at-risk individuals to potentially prevent further damage to beta cells and improve glycemic control. [Extracted from the article]

A recent study conducted by the Wellcome Trust Sanger Institute focused on investigating the misclassification of type 1 diabetes in a population-based cohort of British Pakistanis and Bangladeshis using polygenic risk scores. The study highlighted the challenges in correctly classifying type 1 and type 2 diabetes, especially in South Asians, due to overlapping clinical features and early onset of type 2 diabetes. The research emphasized the importance of routine measurement of diabetes autoantibodies and C-peptide for robust identification of type 1 diabetes cases and appropriate clinical care. [Extracted from the article]

Researchers at the University of Sao Paulo conducted a study on the role of microRNAs in the pathogenesis of type 1 diabetes (T1D). They found that specific miRNAs were highly expressed in patients with T1D compared to healthy individuals, indicating their potential involvement in T1D progression. The study concluded that proliferative, metabolic, and immune responses were the main pathways associated with serum miRNA target genes in T1D. This research was supported by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) and has been peer-reviewed. [Extracted from the article]

The article discusses how a specific gene variant found in four percent of Greenland's Inuit population increases their risk of developing type 2 diabetes by tenfold. This gene variant leads to insulin-resistant musculature, making it challenging to detect pre-diabetic conditions in carriers. The study suggests that physical activity can increase insulin sensitivity in the muscles of gene variant carriers, potentially reducing the risk of diabetes. The research also explores the potential benefits of future medications that could enhance insulin sensitivity for individuals with type 2 diabetes. [Extracted from the article]

The article discusses a phase III clinical trial, NCT06763328, focusing on the use of metformin to treat insulin resistance in women with stage I-III breast cancer after chemotherapy. Insulin resistance is a risk factor for diabetes and heart disease, and higher insulin levels are associated with aggressive breast cancer. Metformin, in combination with standard care, aims to prevent or reverse insulin resistance in these breast cancer survivors. The trial aims to determine if metformin can normalize glycosylated hemoglobin levels and explores potential epigenetic changes and inflammatory cytokine levels. [Extracted from the article]

The article discusses the role of NAMPT activity in driving autoimmune processes in the development of type 1 diabetes in mice. The study suggests that inhibiting NAMPT may be a potential therapeutic approach for type 1 diabetes by protecting islets against cytokine-mediated dysfunction and death. The research findings indicate that NAMPT inhibition could modulate islet autoimmunity and improve glycaemic control in mice. The study has not yet undergone peer review and provides insights into potential novel treatments for type 1 diabetes. [Extracted from the article]

A recent report from the University of Toronto discusses the challenges in treating Type 1 Diabetes (T1D) and the potential benefits of metabolic interventions as adjunctive therapies to insulin. The research highlights the importance of targeting metabolic control to preserve beta-cell function and improve overall metabolic health in individuals with T1D. While insulin remains the cornerstone of T1D treatment, adjunctive metabolic interventions show promise in enhancing glycaemic control, reducing insulin requirements, and potentially halting disease progression. Future research aims to optimize these treatment strategies and establish their long-term efficacy and safety. [Extracted from the article]

The University of Bayreuth conducted research on the use of automated insulin delivery systems in managing type 1 diabetes during physical activity and exercise. The study highlights the importance of regular physical activity for individuals with type 1 diabetes and the challenges posed by glucose fluctuations during exercise. The research, supported by Universitat Bayreuth, provides detailed clinical practice points for managing physical activity in individuals with type 1 diabetes using automated insulin delivery technology. The study was published in Diabetologia and can be accessed online for further information. [Extracted from the article]

Researchers from Ohio University have submitted a patent application for methods involving the use of Fat Specific Protein 27 (FSP27) compositions to regulate muscle performance. FSP27 has been linked to lipid droplets in adipocytes and is associated with improved metabolic health in humans. The application outlines various uses of FSP27 compositions, including improving muscle performance, regulating lipid droplet dynamics, and treating conditions such as insulin resistance, obesity, and dyslipidemia. The patent application aims to provide therapeutic solutions for metabolic diseases and conditions associated with increased free fatty acids and lipotoxicity. [Extracted from the article]

A Phase III clinical trial, NCT06767735, is being conducted by Gan & Lee Pharmaceuticals to compare the efficacy and safety of once-weekly GZR4 and once-daily Insulin Glargine U100 with Non-Insulin Antidiabetic Agents in insulin-naive subjects with Type 2 Diabetes Mellitus. The study aims to assess patient-reported outcomes and includes primary and secondary outcome measures such as changes in HbA1c levels, hypoglycemia events, adverse events, and weight changes. Recruitment for the trial has not yet begun, with an enrollment target of 580 participants and a completion date set for August 17, 2026. [Extracted from the article]

A Phase III clinical trial, NCT06767748, is being conducted to compare the efficacy and safety of once-weekly GZR4 and once-daily Insulin Degludec with or without Non-Insulin Antidiabetic Agents in subjects with Type 2 Diabetes Mellitus (T2DM) treated with basal insulin. The study aims to assess patient-reported outcomes and includes primary outcome measures such as changes in HbA1c levels and secondary outcome measures like hypoglycemia events and adverse events. Recruitment for the study is not yet active, with an enrollment target of 620 participants and a completion date set for February 28, 2026. [Extracted from the article]

The article discusses a Phase III clinical study comparing the efficacy and safety of once-weekly GZR4 and once-daily Insulin Glargine U100 in combination with Insulin Aspart for Type 2 Diabetes Mellitus (T2DM) patients. The study aims to assess patient-reported outcomes and safety measures. The trial is set to enroll 580 participants, with a primary completion date of March 19, 2026. The study is interventional, with a randomized allocation and parallel intervention model. [Extracted from the article]

A recent study led by Dr. Saifur Khan at the University of Pittsburgh has identified molecular mechanisms that contribute to the progression from gestational diabetes to type 2 diabetes. The research focused on Hispanic women with a history of gestational diabetes and found that those who developed type 2 diabetes had reduced levels of sphingolipids in their blood due to a mutation in the CERS2 gene. This discovery could lead to new therapies and interventions to reduce the risk of developing type 2 diabetes after gestational diabetes. The study was supported by various research grants and involved collaboration with multiple institutions and researchers. [Extracted from the article]

A recent study from the University of Pittsburgh found that women who have gestational diabetes are at an increased risk of developing type 2 diabetes after delivery. The researchers identified three distinct molecular drivers that contribute to the development of type 2 diabetes in these women, offering potential targets for precision-medicine approaches. The study, which focused on 225 women, used computational modeling and machine learning to analyze metabolomic, proteomic, and genomic data, as well as clinical measures. This research aims to develop early interventions to prevent the progression from gestational diabetes to type 2 diabetes. [Extracted from the article]

Verily Life Sciences LLC has been issued a patent for systems and methods for gating a step count, which aims to improve the assessment of activity levels for diabetic and pre-diabetic patients. The patent focuses on using acceleration data from an accelerometer to determine the user's movement patterns and step count, particularly within the 2-3 km/h band. By analyzing characteristics of the acceleration data, such as frequency domain characteristics, the system can accurately assess activity levels and provide valuable information for managing diabetes. [Extracted from the article]

A recent study conducted in Wenzhou, China, explored the potential protective effects of eugenol on type 1 diabetes mellitus (T1DM) through the NRF2-mediated oxidative stress pathway. The research found that eugenol, a natural compound, demonstrated anti-inflammatory, anti-oxidant, and anti-apoptotic properties that could effectively reduce pancreatic beta cell damage associated with T1DM. By activating the NRF2 signaling pathway, eugenol showed promise as a potential therapeutic candidate for T1DM. This study highlights the importance of exploring natural compounds for their potential benefits in managing T1DM. [Extracted from the article]

Researchers at the Montreal Clinical Research Institute conducted a study on strategies to reduce hypoglycemic risk during and after aerobic exercise for individuals with type 1 diabetes. The study involved 37 participants and found that continuous moderate intensity exercise led to a greater decrease in blood glucose compared to intermittent exercise. Post-exercise strategies involving insulin reduction and carbohydrate snacks were found to have comparable effects on glucose profiles in individuals with type 1 diabetes. The study was supported by the Canadian Institutes of Health Research and has been peer-reviewed. [Extracted from the article]

A recent report from the Centre for Clinical Intervention Research discusses the comparison between regular human insulins and rapid-acting insulin analogues in children and adolescents with type 1 diabetes. The study aims to assess the beneficial and harmful effects of these insulin types, focusing on glycemic control and risk of hypoglycemic episodes. The research highlights the need for a comprehensive systematic review to evaluate the current evidence on insulin management in young individuals with type 1 diabetes. [Extracted from the article]

A study conducted at the Federal University of Rio Grande do Norte in Brazil explored the potential benefits of passion fruit peel extracts for Type 1 Diabetes mellitus. The extracts, derived from Passiflora edulis fo. flavicarpa, were found to improve glycemic control when used as an adjuvant treatment with insulin in diabetic rats. The research suggests that these extracts could enhance long-term management of Type 1 Diabetes by preventing organ damage and inspiring the development of new food or pharmaceutical products. [Extracted from the article]

A study conducted at the University of Montreal explored the impact of renal tubule-specific deletion of angiotensinogen on diabetic kidney disease in murine models of type 1 diabetes. The research found that mice with this deletion showed improvements in various kidney-related parameters, including glomerular hyperfiltration and tubular injury. The study suggests that targeting the intrarenal renin-angiotensin system may be an effective treatment for diabetic kidney disease. [Extracted from the article]

Recent research from the University of Colorado Denver has explored the use of semaglutide and tirzepatide in overweight and obese adults with Type 1 Diabetes (T1D). The study found that these non-insulin medications led to weight loss and improved glucose control in patients with T1D. The researchers suggest the need for larger, prospective trials to further investigate the safety and efficacy of these drugs in T1D patients. [Extracted from the article]

A recent report from the University of Minnesota discusses research findings on Type 1 Diabetes, highlighting the chronic destruction of insulin-producing beta cells by autoreactive T cells. The study explores a combinatorial approach involving the implantation of a novel biomaterial co-seeded with insulin-producing islets and T regulatory cells (Tregs) in non-obese diabetic mice. Results show increased longevity, insulin secretion, and normoglycemia in mice receiving the co-seeded biomaterial, suggesting the efficacy of this approach in reversing Type 1 Diabetes. The research has been peer-reviewed and offers new insights into potential treatments for this condition. [Extracted from the article]

Researchers from the University of Colorado conducted a study on young adults with Type 1 Diabetes (T1D) to investigate the relationship between impaired insulin sensitivity and kidney oxidative metabolism. The study involved various tests and analyses, revealing early structural and metabolic changes in T1D kidneys that may precede clinical Diabetic Kidney Disease (DKD). The findings suggest that individuals with T1D exhibit lower insulin sensitivity and cortical oxidative metabolism, indicating potential mitochondrial dysfunction. Financial support for the research was provided by various organizations, including the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the Juvenile Diabetes Research Foundation. [Extracted from the article]

A recent study conducted at the University of Miami explored the presence of a glucose fraction independent of insulin secretion in individuals with autoantibodies related to Type 1 Diabetes. The research found that this independent glucose fraction significantly contributes to impaired glucose tolerance and predicts both Type 1 Diabetes and impaired glucose tolerance. The study sheds light on the relationship between glucose and C-peptide levels and provides valuable insights into the progression of Type 1 Diabetes in autoantibody-positive cohorts. [Extracted from the article]

A patent has been issued for pulsed focused ultrasound therapy for the treatment of pancreatic disorders by the Board of Trustees of the Leland Stanford Junior University. This therapy aims to treat diseases such as type 1 diabetes, pancreatitis, and pancreatic cancer by utilizing pulsed focused ultrasound either alone or in combination with islet transplantation and stem cell therapy. The method focuses on increasing insulin secretion, promoting regeneration of damaged pancreatic tissue, and controlling drug release in the pancreas, islets, beta cells, or stem cells. The patent highlights the potential of pulsed focused ultrasound in treating various pancreatic disorders and improving therapeutic outcomes. [Extracted from the article]

Researchers from the Endocrinology Unit in Milan, Italy, conducted a study on the use of smart insulin pens in pregnant women with type 1 diabetes. The study found that the use of smart insulin pens coupled with rt-CGM led to improvements in glucose levels during pregnancy without any severe complications. The researchers highlighted the practical considerations and benefits of using smart insulin pens in managing type 1 diabetes during pregnancy. The study was published in Healthcare and is available for free online. [Extracted from the article]

A study conducted in Tokyo, Japan, focused on a 25-year-old man with slowly progressive type 1 diabetes mellitus (SPIDDM) who showed improved insulin secretion through diet therapy and exercise without medication. Over five years, the patient's body weight decreased, muscle mass increased, and glycated hemoglobin levels improved. The research suggests that lifestyle interventions may help patients with non-insulin-dependent SPIDDM recover and maintain their insulin secretion. [Extracted from the article]

A recent study conducted by the University of Florida examined serological markers of exocrine pancreatic function to distinguish individuals progressing to type 1 diabetes. The research found that lipase and trypsinogen levels were the most informative for differentiating among clinical groups, with their utility varying according to genetic risk score and autoantibody/type 1 diabetes status. These findings suggest that exocrine pancreas enzymes could be valuable candidates for longitudinal follow-up in individuals at risk for type 1 diabetes. [Extracted from the article]

The BBVA Foundation Frontiers of Knowledge Award in Biology and Biomedicine was awarded to four researchers for their groundbreaking work on the GLP-1 hormone, which plays a crucial role in regulating glucose levels and appetite. Their discoveries have led to the development of new drugs for treating type 2 diabetes and obesity, with potential applications in neurological conditions and addiction disorders. The research has significantly advanced the treatment of diabetes and obesity, offering patients more effective and safer options for managing these conditions. [Extracted from the article]

Researchers from Stanford Medicine have developed an artificial intelligence-based algorithm that can identify subtypes of Type 2 diabetes using data from continuous blood glucose monitors. This technology aims to provide personalized preventative measures for individuals with diabetes or prediabetes, allowing for better understanding and management of the condition. The algorithm, which can predict metabolic subtypes with about 90% accuracy, has the potential to improve access to care for those who may be economically challenged or geographically isolated. [Extracted from the article]

A clinical trial, NCT06762314, is being conducted to evaluate the efficacy and safety of Empagliflozin or Semaglutide in overweight/obese patients with Type 1 Diabetes inadequately controlled by insulin therapy. Type 1 Diabetes is characterized by the destruction of insulin-producing pancreatic beta cells, leading to insulin deficiency. Despite advancements in diabetes therapy, many patients struggle to manage their disease and face complications. The trial aims to assess the impact of different treatments on glycated hemoglobin levels over a 3-month period. [Extracted from the article]

The article discusses new research on Type 1 Diabetes (T1D) focusing on immunomodulators for beta cell restoration and autoimmune response suppression. It highlights investigational drugs like teplizumab and other immunomodulators tested in clinical trials for T1D treatment and islet transplantation. The research provides insights into the mechanism of action, trial results, adverse effects, and ongoing clinical trials for these immunomodulators. The study aims to identify promising therapies for T1D and islet transplantation. [Extracted from the article]

The article discusses research on beta cell dysfunction in type 1 diabetes, highlighting that dysfunction occurs independently of T cell infiltration. The study used live human pancreas tissue slices to examine beta cell function in donors with and without diabetes. The findings suggest that beta cell metabolic defects contribute to dysglycemia in type 1 diabetes, regardless of T cell infiltration. The research has not yet been peer-reviewed. [Extracted from the article]

A recent study conducted at the Saveetha Institute of Medical and Technical Sciences in Tamil Nadu, India, focused on the effectiveness of self-care in adolescents with type 1 diabetes. The research aimed to improve knowledge of insulin administration, reduce anxiety levels, and decrease depression among individuals with type 1 diabetes. The study utilized quantitative research methods and found significant improvements in insulin administration, depression, and anxiety levels in the experimental group compared to the control group. This research highlights the importance of self-care activities in managing type 1 diabetes among adolescents. [Extracted from the article]

A recent study conducted at the Jaeb Center for Health Research in Tampa, Florida, explored sex differences in glycemia and self-management strategies for exercise in adults with type 1 diabetes. The research found that female participants had higher pre-exercise glucose levels compared to males and experienced smaller glucose declines during personal exercise. Despite these differences, there were no observable variations in food, exercise, and insulin habits between the sexes. This peer-reviewed study sheds light on the impact of sex on glucose levels and exercise management in individuals with type 1 diabetes. [Extracted from the article]

Spitfire Pharma LLC has been issued a patent for therapeutic regimens and methods aimed at lowering blood glucose and body weight using GLP-1R and GCGR balanced agonists. The patent addresses the increasing prevalence of obesity, diabetes mellitus, and related conditions, emphasizing the need for safe and effective pharmaceutical treatments. The dual agonist peptides described in the patent offer potential benefits for treating disorders associated with obesity and diabetes, such as NASH and PCOS, by targeting GLP-1R and GCGR. The patent outlines methods for reducing body weight and controlling blood glucose levels in humans, with a focus on minimizing adverse events and achieving weight loss. [Extracted from the article]

The article discusses a patent issued to Laxmi Therapeutic Devices Inc. for applicators designed to facilitate the attachment of glucose monitors to a person's body for monitoring glucose levels, particularly in individuals with type 1 or type 2 diabetes. The patent describes an applicator assembly that includes a frame, a resilient member, a needle, and a cap to aid in the insertion of the sensor under the skin. The invention aims to improve the precision, wearability, and accessibility of glucose monitors for end-users, especially for continuous glucose monitors that need to remain attached to the body for an extended period. [Extracted from the article]

A new study discusses the development of a novel peripherally acting alpha2A-adrenergic receptor antagonist, CDS479-2, as a potential treatment for type 2 diabetes. This derivative of yohimbine shows similar antagonist activity to yohimbine but with limited access to the brain, reducing unwanted central side effects. In animal models, CDS479-2 demonstrated the ability to lower blood glucose levels, improve glucose tolerance, sustain normoglycemia, and increase insulin-producing beta cells, suggesting a promising direction for type 2 diabetes treatment. The study also highlights the potential for optimizing drugs with both peripheral and central targets in the future. [Extracted from the article]

A recent study conducted by the Luxembourg Institute of Health examined the impact of automated insulin delivery systems (AIDs) on diabetes distress (DD) in individuals with type 1 diabetes and their caregivers. The research, which included 40 studies with over 5,000 participants, found that AIDs were associated with a reduction in DD among adults and caregivers, but not in children or teenagers with type 1 diabetes. The study suggests the need for more longitudinal research and improved systematic assessments of DD in this population. [Extracted from the article]

A recent study from the University of Bayreuth in Germany explores the use of automated insulin delivery systems in managing type 1 diabetes during physical activity and exercise. The study emphasizes the importance of physical activity for individuals with type 1 diabetes and discusses the challenges and benefits of using automated insulin delivery systems in maintaining glucose levels within target ranges during exercise. The research provides detailed clinical practice points for managing physical activity in children, adolescents, and adults with type 1 diabetes using this technology. [Extracted from the article]

A study conducted at Mutah University explored the experiences of parents caring for young children with type 1 diabetes in an Arab country. The research highlighted the challenges faced by parents in adapting to their child's diagnosis, managing treatment regimens, and coping with psychological, social, and financial burdens. The study emphasized the need for support for parents navigating the complexities of caring for a child with type 1 diabetes. [Extracted from the article]

A recent study conducted at Mohammed VI University Hospital in Marrakech, Morocco, focused on the prevalence and clinical significance of autoantibodies in type 1 diabetes (T1D) patients. The research, which included 276 T1D patients, found an overall autoantibody seropositivity rate of 75.36%, with anti-glutamic acid decarboxylase (GAD65) antibodies being the most prevalent. The study highlighted the importance of detecting autoantibodies in T1D patients to predict the onset of the disease and associated autoimmune disorders. [Extracted from the article]

A recent study conducted by Harvard Medical School researchers focused on adults with type 1 diabetes and their ability to achieve glycemic targets using continuous glucose monitoring (CGM) data. The study found that despite the use of diabetes technologies, a significant portion of participants were unable to reach their glycemic targets and experienced severe hypoglycemia. The research highlights the ongoing need for innovative treatments in managing type 1 diabetes. For more information, the full article can be accessed through the Diabetes Care journal. [Extracted from the article]

Researchers from NU Hospital Group have reported findings on the potential role of leukotrienes in the pathogenesis of type 1 diabetes, specifically in reducing insulin requirements in patients. A case study involving a 55-year-old male with Latent Autoimmune Diabetes in Adults (LADA) showed significant reductions in insulin dosage when treated with montelukast, a leukotriene receptor antagonist, for respiratory symptoms. The study suggests that montelukast may have anti-inflammatory effects on eosinophils, highlighting the need for further research into its role in managing type 1 diabetes and potentially reducing insulin dependence. [Extracted from the article]

A recent study conducted by researchers at the University of California explored the use of Glucagon-Like Peptide 1 receptor agonists (GLP-1 RAs) as an adjunct therapy for Type 1 Diabetes (T1D) in adolescents and young adults. The study found that GLP-1 RAs, such as semaglutide and tirzepatide, improved glycemic control, reduced insulin needs, and supported weight management in patients with T1D. However, some patients experienced gastrointestinal side effects and one developed an eating disorder, emphasizing the importance of careful monitoring. The research suggests that GLP-1 RAs could be a beneficial addition to T1D treatment, potentially preventing long-term cardiovascular and renal complications. [Extracted from the article]

A recent study conducted at Campus Bio-Medico University of Rome focused on the metabolomic signature of pediatric diabetic ketoacidosis (DKA) in patients with type 1 diabetes (T1D). The research highlighted significant metabolic disturbances in severe DKA and their associations with critical clinical indicators. The study utilized plasma metabolomics to identify predictive metabolite patterns and found that metabolomics profiling accurately differentiated severe DKA from insulin-controlled states. The findings suggest that metabolic alterations in severe DKA could potentially help identify patients at increased risk of complications and guide future therapeutic interventions. [Extracted from the article]